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Abstract
Among the challenges facing translational medicine today is the need for greater productivity and
safety during the drug development process. To meet this need, practitioners of translational
medicine are developing new technologies that can facilitate decision making during the early stages
of drug discovery and clinical development. Ex Vivo Metrics™ is an emerging technology that
addresses this need by using intact human organs ethically donated for research. After hypothermic
storage, the organs are reanimated by blood perfusion, providing physiologically and biochemically
stable preparations. In terms of emulating human exposure to drugs, Ex Vivo Metrics is the closest
biological system available for clinical trials. Early application of this tool for evaluating drug
targeting, efficacy, and toxicity could result in better selection among promising drug candidates,
greater drug productivity, and increased safety.
Introduction
Recently, much attention has been given to productivity
and safety issues hampering the development of effective
new treatments by the pharmaceutical industry. Drug
development is prohibitively expensive, mainly due to
high attrition rates during clinical trials [1,2]. In response
to this, as well as to recent, high-profile safety and toxicity
issues [1,3], many companies have chosen to avoid risk by
making incremental improvements to existing products
rather than focusing on innovation and expansion based
on exploratory research.
Practitioners of translational medicine are addressing the
productivity and safety obstacles to drug development by
encouraging multidisciplinary debate to surface the right
questions and then applying the right tools to derive
answers [4]. The right questions are those that direct the
next step of drug development by providing sufficient
information to support either continuation or termina-
tion of the development of a particular drug candidate.
The right tools are those that generate reliable, interpreta-
ble data to enhance the success rate and productivity of
drug development.
Particularly important among tools of translational
research are those capable of improving early decision
making, such as by determining human relevancy and
predictability or by selecting the best drug from among
several promising candidates. Although many technolo-
gies and approaches, such as attrition rate modeling,
proof-of-concept strategies, combinatorial chemistry, and
pharmacogenomics, have initially shown promise in
improving productivity, most have not lived up to expec-
tations. For example, pharmacogenomics is a powerful
tool for determining which patients are most likely to
benefit from a given drug, but this technology has neither
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improved the quality of drug candidate selection nor lim-
ited candidate failure. Likewise, effective computer simu-
lation can be a valuable tool, but is more beneficial for
drug design than drug discovery. Predictive surrogates,
improved biomarkers, and better animal models have
proved useful for early decision making in certain situa-
tions, but, in some cases, are difficult to identify or vali-
date and have questionable relevancy to humans.
One technology that could potentially improve the pro-
ductivity and safety of drug development is Ex Vivo Met-
rics™. Based on ex vivo models with direct relevance to
humans, Ex Vivo Metrics serves as an excellent example of
the concept of research translating into practical applica-
tion. Here we describe the technology, including its capa-
bilities, advantages, and limitations.
Ex Vivo Metrics technology
Ex Vivo Metrics technology is a novel, humanized preclin-
ical test platform designed to enhance drug development.
This blood-perfused system maintains isolated, intact
human organs in a viable state (Figure 1), allowing com-
pounds to be tested without the extrapolations associated
with animal studies and in vitro systems or the risks asso-
ciated with early human trials.
Although the development of similar perfusion systems in
animals has been relatively straightforward, human
whole-organ perfusion is complicated by issues related to
organ procurement, transport, and revitalization. Ex Vivo
Metrics uses only ethically-donated-for-research human
organs made available through organ transplant programs
but considered unsuitable for transplant. The donation of
organs for research by individuals and families comes,
rightly, with an expectation that these donated organs will
be used, as far as is realistically possible, to generate rele-
vant data that will benefit healthcare. This responsibility
is not taken lightly. Organ transport is accomplished with
continuous perfusion using the same techniques, equip-
ment, and solutions employed prior to actual transplanta-
tion. For reanimation, oxygenated, matched whole blood
containing the relevant biochemical substances for a
given organ is perfused via the appropriate vasculature at
the temperature, pressures, and flow rates that most
closely replicate physiologic conditions [5]. Organs com-
monly and successfully perfused for Ex Vivo Metrics
include the liver, intestine, and lung (Figure 1).
The application of Ex Vivo Metrics to drug studies
For drug studies, a blood-perfused organ that meets the
acceptance criteria is dosed through an appropriate route,
and samples are collected for analysis (Table 1). Biopsies
and blood samples are obtainable, as are tissue-specific
samples, such as gut contents (intestine), bile (liver), and
airway lavage (lung). The intestine and lung have been
used to study drug absorption; the liver, intestine, and
Perfusion platforms used by Ex Vivo Metrics technology for the lungs (A), intestines (B), and liver (C) Figure 1
Perfusion platforms used by Ex Vivo Metrics technology for the lungs (A), intestines (B), and liver (C). Each 
device includes an artificial thorax that meets the specific needs of the organ. For the lung (A), the artificial thorax allows for 
positive and negative ventilation and continuous lung function testing; for the intestines (B), it permits recording of active peri-
stalsis; for the liver (C), it provides a heavy organ support system for reducing surface-contact pressure effects.
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lung to study metabolism; and the lung to study toxicity
and efficacy.
To perform these studies, each organ must act as its own
control. Unlike inbred animals strains matched for age,
gender, diet, and environmental conditions, organs from
different individuals, when exposed to drug candidates,
will most certainly have quantitative differences. Often
this is not appreciated until after the completion of clini-
cal trials or during the performance of postmarketing sur-
veillance. In practice, an organ acting as its own control
means that whatever process is being studied, whether
drug targeting, efficacy, and/or safety, appropriate positive
and negative standards must also be applied. These stand-
ards are added before, during, or after test compounds are
administered, depending on which timing is most appro-
priate. For example, in human gut absorption studies, pas-
sively absorbed standards with known differential rates of
absorption can be coadministered with test substances for
comparison. In metabolism and clearance studies, stand-
ards can be added after the majority of test substances are
washed out. Likewise, for efficacy and toxicity studies, any
lack of effect by new drug entities on human organs can
be confirmed in the same organ by standards with well-
documented activities. In this way, all blood-perfused
human organs that satisfy the physiologic and biochemi-
cal criteria and are deemed viable for dosing should gen-
erate relevant, reliable, and predictable human data.
With regard to the volume of test compounds studied, it
should be noted that Ex Vivo Metrics is not a high-
throughput system. However, when combined with cas-
sette dosing, this system enables thousands of drug candi-
dates to be evaluated annually.
Comparison to other methodologies
Ex Vivo Metrics has several advantages over other test sys-
tems currently in use for drug discovery (Table 2). The
human organ perfusion model is, of course, highly rele-
vant to humans and thus easier to extrapolate to the
whole human than are whole animal and animal ex vivo
perfusion studies. The Ex Vivo Metrics system is also func-
tionally superior to tissue- and cell-based assays because it
provides a full complement of intact physiologic func-
tions and conditions, including the presence of the extra-
cellular matrix, vasculature, and hormonal and other
endogenous substances. In the future, Ex Vivo Metrics will
be adapted to study diseased organs, including those with
viral or bacterial infections, inflammation, tumors, or
metabolic conditions such as diabetes; this capacity, once
developed, will be of tremendous value, particularly when
suitable animal models are limited or unavailable [5].
Ex vivo organ studies also have several advantages over
human in vivo studies in terms of drug development. For
example, ex vivo organ studies allow one to observe the
immediate impact of a compound at the organ level and
to separate out individual components of a gross effect.
This provides a greater understanding of the way in which
the drug interacts with selected human systems and the
effects that such systems have on each other. By compari-
son, in a clinical trial setting, only the overall effect of a
drug may be observed. Perfusion of isolated organs also
permits greater control over the drug concentration
applied to the organ and over other parameters related to
the perfusate and the organ. For example, the contribu-
tions of diet, age, and drug dose can be systematically
evaluated [5]. Multiple compounds can also be tested
simultaneously to identify the potential for drug-drug
Table 1: Perfusion Overview
Organs Blood Input Acceptance Criteria Dosing Routes Samples for Analysis
Lungs • Pulmonary artery
• Bronchial artery
• Perfusion pressures
• Flow rates
• Compliance
• Resistance
• Airway pressures
• Blood chemistry and 
biochemistry
• Airways
• Blood
• Blood/plasma
• Airway lavage
• Biopsies
Liver • Portal vein
• Hepatic artery
• Perfusion pressures
• Flow rates
• Bile flow
• Blood chemistry and 
biochemistry
• Blood • Blood/plasma
• Bile
• Biopsies
Intestine • Superior mesenteric 
artery (or its branches)
• Perfusion pressure
• Flow rate
• Active peristalsis
• Blood chemistry and 
biochemistry
• Gut lumen
• Blood
• Blood/plasma
• Gut contents
• BiopsiesJournal of Translational Medicine 2008, 6:5 http://www.translational-medicine.com/content/6/1/5
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interactions [5]. Advantages related to data collection
include the ability to continuously monitor the system
during experimentation and the ease of sample collection.
First-pass or recirculated samples of effluate are straight-
forward to obtain, as are tissue biopsies.
Ex Vivo Metrics technology also has certain limitations.
One limitation of this technology is that the perfused
organs are severed from the host immune and central
nervous systems. Some toxicity outcomes, such as bacte-
rial and viral infections, involve an interplay between the
invading organism and host immunity, particularly cell-
mediated immunity. In situations such as these, the cho-
sen human organs may not fully simulate natural infec-
tions. However, some aspects of the immune system and
nervous system are maintained or can be simulated with
Ex Vivo Metrics. For example, an appropriate innate
immune response is present in some organs, and the per-
fusion systems allow immune cells from histocompatible
individuals to be infused in a controlled manner to evalu-
ate their contribution to toxicity. Similarly, the contribu-
tion of nerve stimulation to toxicity can be reproduced by
electrical stimulation of the appropriate nerves. However,
these studies have not yet been evaluated in drug candi-
date targeting, efficacy, and safety.
Aims and outcomes of Ex Vivo Metrics in drug studies
Ex Vivo Metrics serves as an example of translational med-
icine in action through its use of basic research to poten-
tially enhance the drug development process. An
important aim of Ex Vivo Metrics is more efficient drug
candidate selection, facilitated by testing compounds in
human organs prior to clinical trials, so that possible fail-
ures can be eliminated at an earlier stage before significant
expenditure has been made. Ex Vivo Metrics could also be
applied to early-stage drug discovery to select, rank, and
profile drug candidates. The technology could be used to
generate metabolic, safety, and drug-drug interaction data
complementary to information obtained through other
systems.
Ex Vivo Metrics also offers the safety reassurances of
allowing drugs to be tested and human data generated
prior to human exposure and its associated risks. This is
especially critical for humanized biologicals, for which
traditional preclinical assessments may not be particularly
informative. The ex vivo isolated blood-perfused human
organ model also can help to explain divergent clinical
and preclinical outcomes. For example, the system can be
used to further study a drug candidate that fails in clinical
trials after yielding promising results in preclinical studies
to investigate the reasons why the failure occurred; this
new understanding can then be applied to future candi-
date selections. Finally, in certain situations, Ex Vivo Met-
rics can function as an efficacy model when alternatives
are not readily available or when knowledge of pharmaco-
dynamic effects in a human setting is considered to be
particularly important.
Conclusion
Addressing the productivity and safety challenges of drug
development will require a multidisciplinary approach,
asking the right "go/no-go" questions, and having availa-
ble the right tools to answer these questions in a reliable
and relevant way. In addition to the tools already being
used effectively, such as biomarkers, ex vivo human whole
organ perfusion could potentially help to bridge the gap
between preclinical and clinical drug development phases
by providing specific and directly relevant pharmacoki-
netic, safety, and efficacy data before human trials begin.
Such a system could allow rapid selection among promis-
ing drug candidates, resulting in increased productivity,
and could promote increased safety. However, for Ex Vivo
Metrics to be of maximum value to translational medi-
cine, it will be necessary to prove that this technology (1)
meets reliability, reproducibility, and predictability expec-
tations; (2) provides robust and easily interpreted data;
and (3) delivers tangible efficiency and effectiveness gains
in a realistic time frame.
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Table 2: Comparison of Ex Vivo Metrics to Other Test Systems
Human Ex 
Vivo Metrics
Whole Animal Animal Ex 
Vivo Perfusion
Organ Baths Tissue Slices Cells Subcellular 
Systems
Relevance to target species ● -- ●● ● ●
Physiologic functions ●●●-- - -
Nervous ❍● ❍-- - -
Hormonal (relevant) ●●● ● -- -
Vasculature ●●●-- - -
Full cell complement ●●● ● ● --
Extracellular matrix ●●● ● ● --
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